✨ Free AI Report
Affimed N.V.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Affimed N.V.
Research Preview

Affimed N.V.: Business Overview, Financials & Competitive Analysis

Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. The company's proprietary, next-generation bispecific antibodies, called TandAbs, are...

Analyst-debate audio for Affimed N.V.

AskCyborg analysts argue the bull and bear cases for Affimed N.V. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Affimed N.V. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
6/ 10Solid

Cyborg Score thesis

Clinical-stage immuno-oncology leader with multi-program pipeline, strong partnerships, and promising early-stage data in...

Read the full analyst-debate transcript →
Industry Oncology Drugs
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Affimed N.V. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Affimed N.V. Overview

Pro stress-test →

Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. The company's proprietary, next-generation bispecific antibodies, called TandAbs, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. The company develops novel immuno-oncology therapeutics leveraging innate immune mechanisms for multiple cancer indications.

Strategic Profile

Pro stress-test →

Affimed collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers. The company has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK, and a strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology. These partnerships position Affimed to advance multiple programs while managing development risk and accessing complementary capabilities.

Competitive Landscape

Pro stress-test →

Affimed's NK cell and T-cell engager platform competes in the immuno-oncology space, where bispecific antibody technology bridges immune effector cells to cancer targets. Key competitors include Genmab, Regeneron, Amgen, and Astellas in bispecific antibody and NK cell engager development. Affimed's partnerships with Genentech and others reflect industry consolidation and co-development strategies common in clinical-stage oncology.

Industry Context

Affimed N.V. operates in Oncology Drugs.

Key facts

Founded: 2000 · Headquarters: Heidelberg, Germany · Employees: N/A · Revenue: Estimated $0–$10M (clinical-stage; no product revenues) · Market cap: N/A

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Affimed N.V..

+1 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Affimed N.V. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Bispecific antibodies / NK cell engagersBispecific antibodies and NK cell-engaging immunotherapies→Bispecific antibodiesBispecific and multispecific antibodies for oncology→Bispecific cancer immunotherapiesBispecific antibodies and immuno-oncology programs→

Compare Affimed N.V. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Affimed N.V. operates in Oncology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology Drugs research →
NEW · MCP server

Ask your AI assistant about Affimed N.V.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Affimed N.V. and its top competitor on Cyborg Score”
“What did Affimed N.V. do this quarter?”
“Is Affimed N.V. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Affimed N.V. do?+
Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. The company's proprietary, next-generation bispecific antibodies, called TandAbs, are...
What is Affimed N.V.'s Cyborg Score?+
Affimed N.V. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Affimed N.V.'s main competitors?+
Named competitors include Bispecific antibodies / NK cell engagers, Bispecific antibodies, Bispecific cancer immunotherapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Affimed N.V. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Affimed N.V. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Affimed N.V. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.